Navigation Links
Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association

CHENGDU, Sichuan, China, April 21 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical (NYSE Amex: TPI) was invited by Sino American Biopharmaceutical Association (SABPA) to present at its 5th Annual Biomedical Forum held at Irvine, California on April 24th, 2010. SABPA Biomedical forum focuses on innovations in pharmaceutical and biotechnology industries, as well as business opportunities to thrive in the new economy. The forum provides an attractive platform for entrepreneurs, scientists, investors, executives and policy makers to promote life sciences, biotechnology, pharmaceutical, medical devices and alliances across the biomedical industry.

"We appreciate the invitation by SABPA to interface with a large audience of industrial professionals, entrepreneurs and healthcare investment funds," said Dr. James J. Tong, Chief Financial Officer and Chief Business & Development Officer of Tianyin, "Since 2005, SAPBA conferences have been the forefront to bridge biopharmaceuticals and innovations between the healthcare industry of US and China. We look forward to the in-depth interaction with the biopharmaceutical community in US."

Dr. Jiang, Guoqing, Chairman and CEO of Tianyin Pharmaceutical pointed out, "The past 10 years have seen the rapid expansion of China health care industry, propelled by the economic growth in China, favorable government policies and accelerated demands for pharmaceuticals resulted from an increasing urbanization of a growing population. The ongoing healthcare reform provides further momentum for both generic medicines as well as innovative biopharmaceuticals. Tianyin is positioned to explore the opportunities on both fronts."

SAPBA meeting on 24th of April, McDonald Auditorium, University of California, Irvine from 8:30 am till 4:30 pm (

About Tianyin Pharmaceuticals

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading biopharmaceutical company that is engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics, equipped with two state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 50 products, of which 22 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. Tianyin achieved 10 new drug approvals at SFDA in 2009 and has a pipeline of 12 products pending regulatory approval that target various indications with considerable market potential. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    Investors Contact:
     James Jiayuan Tong  M.D. Ph.D.
     Chief Financial Officer, Chief Business & Development Officer
     Tianyin Pharmaceutical Co., Inc.
     Tel:   +86-28-8551-6696
            +1-949-350-6999 (U.S.)

     23rd Floor Unionsun YangKuo Plaza
     No 2 Block 3 South Renmin Road
     Chengdu, 610041

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
2. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
3. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
4. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
Breaking Medicine News(10 mins):